Diabetes Research and Clinical Practice, Год журнала: 2023, Номер 202, С. 110777 - 110777
Опубликована: Июнь 15, 2023
Язык: Английский
Annals of Internal Medicine, Год журнала: 2023, Номер 176(8), С. 1067 - 1080
Опубликована: Июль 24, 2023
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) decrease serum urate levels, but whether this translates into prevention of recurrent flares among patients with gout and gout-primary emergency department (ED) visits or hospitalizations is unknown.
Язык: Английский
Процитировано
29
Diabetes Obesity and Metabolism, Год журнала: 2022, Номер 25(4), С. 1002 - 1010
Опубликована: Дек. 14, 2022
To investigate changes in the pattern of drugs used to treat type 2 diabetes Denmark from 2005 2021.A nationwide, population-based drug utilization study based on medical databases covering Danish population was conducted. We assessed incident and prevalent use patterns among all 441 205 individuals initiating at least one non-insulin, glucose-lowering drug.The rate new users increased 2005, peaked 2011, decreased stable levels during 2013 2019, then dramatically 2020-2021. The prevalence 2.1% (in 2005) 5.0% 2021) entire adult population. In 2021, metformin comprised 39% consumption, followed by insulin (17%), sodium-glucose co-transporter-2 inhibitors (SGLT-2is) glucagon-like peptide-1 receptor agonists (GLP-1RAs) (16%) dipeptidyl peptidase-4 (7.5%). Overall, 56% were monotherapy, 28% dual therapy, while 13% 2.8% three four classes, respectively. Both intensity diversity therapies substantially over time, with 15 different treatment regimens each more than 1% 2021. General practitioners prescribed 88% drugs. Marked shifts towards GLP-1RA initiation general SGLT-2i specialists observed, changing user profiles suggested increasing for non-diabetes indications.The has recent years increases steadily. Glucose-lowering are mainly practitioners, intensity, indications increasing.
Язык: Английский
Процитировано
29
Clinical and Translational Science, Год журнала: 2025, Номер 18(3)
Опубликована: Март 1, 2025
ABSTRACT The risk of psoriasis in diabetic patients has rarely been explored. This study aims to compare the incident with Type 2 diabetes (T2D) who initiate dipeptidyl peptidase‐4 inhibitors (DPP‐4is) or thiazolidinediones (TZDs) those sulfonylureas, most common second‐line glucose‐lowering therapy, addition metformin monotherapy. sequential, propensity‐score‐matched, new‐user comparative effectiveness utilized a target trial emulation framework. It included adults T2D receiving monotherapy, using data from 2006 2015 general population database Taiwan. primary outcome was incidence psoriasis, determined through diagnoses recorded urgent care, hospital, and outpatient department records. Cox proportional hazards Poisson regressions 1:4 propensity score matching employed evaluate factors for after adjusting comorbidities use other medications. In 49,810 score‐matched (27,630 men [55.4%]; mean age 57.5 years) identified database, rate DPP‐4i users 188 cases per 100,000 person‐years, lower than sulfonylurea (467 person‐years), hazard ratio(HR) 0.422 (95% CI, 0.273–0.716). For TZD vs. comparison, HR 0.35, but smaller matched dataset resulted wide confidence intervals. findings suggest that DPP‐4is is associated compared sulfonylureas T2D. These results can guide selection therapies are at developing psoriasis.
Язык: Английский
Процитировано
0
European Journal of Clinical Pharmacology, Год журнала: 2025, Номер unknown
Опубликована: Март 13, 2025
Abstract Purpose Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained considerable media attention, but there is limited knowledge about those receiving the drugs. This study aimed to assess demographic characteristics and previous diagnoses in patients dispensed GLP-1 RAs Region Stockholm, Sweden, between 2019 2023, with a focus on off-label prescribing. Methods was register-based cross-sectional including all inhabitants who were RA 2023. Patient assessed through record linkage administrative healthcare data demographics, consultations, diagnoses, other Results The prevalence proportion of dispensations Stockholm increased from 4.7 patients/1000 17.5 incidence 1.8 7.4 become more common among younger female population, women constituting 47% incident compared 53% most diagnosis shifted type 2 diabetes mellitus (T2DM) (82% 2019) obesity (47% 2023). During same period, without T2DM notably 10 31%. Almost one-third (31%) drugs 2023 had no recorded either or obesity, 8% 2019. Conclusion showed an increase dispensation RA, changing towards higher degree use. effectiveness safety increasing prescriptions warrant future studies.
Язык: Английский
Процитировано
0
International Journal of Biological Macromolecules, Год журнала: 2024, Номер 265, С. 130962 - 130962
Опубликована: Март 17, 2024
Combining a Sodium-Glucose-Cotransporter-2-inhibitor (SGLT2i) with metformin is recommended for managing hyperglycemia in patients type 2 diabetes (T2D) who have cardio-renal complications. Our study aimed to investigate the metabolic effects of SGLT2i and metformin, both individually synergistically. We treated leptin receptor-deficient (db/db) mice these drugs two weeks conducted metabolite profiling, identifying 861 metabolites across kidney, liver, muscle, fat, plasma. Using linear regression mixed-effects models, we identified SGLT2i-specific metabolites, X-12465 3-hydroxybutyric acid (3HBA), ketone body, all examined tissues. The levels 3HBA were significantly higher under monotherapy compared controls attenuated when combined metformin. observed similar modulatory on involved protein catabolism (e.g., branched-chain amino acids) gluconeogenesis. Moreover, combination therapy raised pipecolate levels, which may enhance mTOR1 activity, while modulating GSK3, common target inhibition. also led significant reductions body weight lactate contrasted monotherapies. findings advocate approach better manage muscle loss, risks DKA lactic acidosis, presenting more effective strategy T2D treatment.
Язык: Английский
Процитировано
3
JAMA Internal Medicine, Год журнала: 2024, Номер 184(6), С. 650 - 650
Опубликована: Апрель 15, 2024
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are a revolutionary treatment for diabetes (T2D) with cardiovascular, kidney, and serum urate-lowering benefits.
Язык: Английский
Процитировано
3
Diabetes Research and Clinical Practice, Год журнала: 2023, Номер 202, С. 110742 - 110742
Опубликована: Июнь 1, 2023
Язык: Английский
Процитировано
7
Diabetes Obesity and Metabolism, Год журнала: 2024, Номер unknown
Опубликована: Сен. 16, 2024
Abstract Aim To analyse patterns of glucose‐lowering therapies among people with type 2 diabetes (T2D) in Denmark from 2016 to 2023. Materials and Methods We examined time trends the clinical profiles T2D who initiated different therapy classes for first time. furthermore investigated individual‐level treatment trajectories following first‐ever or without cardiorenal disease. The study utilized data nationwide Danish health registries included all individuals filled a prescription metformin, dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is) insulin, excluding those HbA1c‐confirmed probable 1 diabetes. Results 260 393 initiating new class 2023, during which there were 6‐ 3‐fold increases initiators GLP‐1RAs SGLT‐2is, respectively. median HbA1c level at initiation SGLT‐2is decreased, 67‐68 mmol/mol 2016‐2017 57‐58 2022‐2023. Among metformin as first‐line therapy, proportion started additional within years increased 25% 40% 2021. 38% had established disease when they 2020, 22% used 18% after 2.5 years, compared 17% 21% disease, Conclusions Our documents trend towards earlier intensification an increase use Denmark. However, optimal is still not received by most early
Язык: Английский
Процитировано
2
Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 21, 2024
Abstract For many years, pharmaceutical expenditure has been the second largest cost item for statutory health insurance funds (SHI) in Germany after hospital costs. Since prescriptions and on medicines play such a major role German healthcare system, question arises as to what causes changes prescriptions. To answer this question, prescribing trends top 10 drugs 2022 were analyzed over period of 38 from 1985 2022. The prescribed defined daily doses (DDD) costs per dose taken Arzneiverordnungsreport (AVR) 1986 2023, behavior their analyzed. ten most important 2022, accounting 41% all doses, ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, metoprolol. There are different reasons an increase prescriptions, introduction generics, positive study, or price reduction. Further extension indication recall competing medicine. A change guidelines increasing treatment laboratory values without clinical symptoms can also lead drop generic launch competitor medicine study Other negative discussion about use drug. Sometimes, prescription irrational. Overall, is comprehensive long-term analysis drug Germany. Our data helpful predicting preventing future shortages not only but worldwide.
Язык: Английский
Процитировано
2
Biomedicine & Pharmacotherapy, Год журнала: 2023, Номер 168, С. 115650 - 115650
Опубликована: Окт. 7, 2023
Язык: Английский
Процитировано
6